Altered expression of members of the IGF-axis in hepatoblastomas by Gray, S G et al.
Hepatoblastoma is a rare malignant childhood tumour of the liver
and accounts for approximately 1–2% of all malignant tumours in
children. The tumour is believed to be embryonic in origin, and
accounts for more than 25% of all paediatric hepatic tumours and
for nearly 50% of malignant liver neoplasms in this age group
(Sainati et al, 1998). Although characterized by a wide spectrum
of subtypes, the majority of hepatoblastomas are composed princi-
pally of epithelial cells that resemble fetal and embryonal hepato-
cytes which are often admixed with mesenchymal cells (von
Schweinitz et al, 1994). The prognosis for affected children has
improved drastically in the last few years but even so, approxi-
mately 25% of all affected children do not survive the disease.
Loss of heterozygosity (LOH) at 11p has been extensively
studied for the chromosomal region 11p15.5 in hepatoblastomas.
This region contains the insulin like growth factor (IGF2) and H19
(a putative tumour supressor) genes, both of which have been
shown to be important in tumorigenesis (for reviews see De Souza
et al, 1997; Looijenga et al, 1997). Both genes are subject to a
phenomenom known as genomic imprinting, a situation in which
expression of a gene is dependent upon the parent of origin (for
reviews see Franklin et al, 1996; Constancia et al, 1998). Loss of
imprinting (LOI) and LOH have been reported for IGF2 and H19
in hepatoblastoma (Albrecht et al, 1994; Montagna et al, 1994;
Li et al, 1995; Rainier et al, 1995). The expression of these genes
have also been shown to be altered in hepatoblastoma. We and
others have observed that H19 was down-regulated in hepato-
blastomas (Albrecht et al, 1994; Montagna et al, 1994; Li et al,
1995) whilst some studies have seen no alteration in its expression
(Rainier et al, 1995; Yun et al, 1998).
IGF-II plays a key role in mammalian growth and fetal cell divi-
sion (Odell and Day, 1998), and its expression is frequently altered
in cancers and overgrowth disorders (Morison and Reeve, 1998).
IGF2 contains four promoters (P1–P4) which are utilized in a
developmental and tissue specific fashion. In hepatoblastomas,
expression from promoters 1 and 4 were shown to have decreased,
whilst that of promoters P2 and especially P3 were up-regulated
(Li et al, 1995). Up-regulation of IGF2 was originally observed to
be occurring in poorly or moderately differentiated hepato-
blastoma cells and in those tumours associated with epithelial
differentiation (Akmal et al, 1995). A recent study showed that the
expression of IGF2 (at least for promoters 1 and 3) occurs in
hepatocytes surrounding the central vein. No expression of IGF2
was observed in haematopoietic, bilary duct or vascular endothe-
lial cells (Yun et al, 1998).
A series of proteins which affect the insulin-like growth factors is
the insulin-like growth factor binding protein family. This family
consists of two subgroups, with six insulin-like growth factor
binding proteins (IGFBPs 1–6), and nine insulin-like growth factor
binding protein related proteins (IGFBP-rPs 1–9), whose common
property is their ability to bind insulin-like growth factors 1 and 2
(IGF-1 and IGF-2) and modulate many aspects of the IGF-axis
(Wetterau et al, 1999). Overexpression of IGFBP-2 has been previ-
ously observed in hepatoblastoma correlating with the degree of
tumour cell differentiation (Akmal et al, 1995).
In this study, we examined the expression of several members of
the IGF-axis in a series of well characterized hepatoblastomas
with corresponding normal liver tissue taken from the same indi-
vidual for most of the samples. In most of these cases, the results
show that the primary difference between normal liver tissue and
hepatoblastoma tissue is a reduction in IGF-binding protein
mRNA levels.
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Summary Previous reports have demonstrated that expression of insulin-like growth factor 2 (IGF2) is altered in hepatoblastoma. Using
RNAase protection analysis (RPA), we examined the gene expression for IGF1, IGF2, IGF1R, M6P/IGF2R, IGFBP-1 and IGFBP-2 in a series
of hepatoblastomas with corresponding normal liver from the same individuals. The results show that the expression of the IGF-axis members
included in the present study are altered between tumour and normal, and indicate that the IGF-axis may be involved in hepatoblastoma
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Samples
All tumours with the exception of the HB6, HB7 and HB8, were
freeze-sectioned into 1 mm portions interrupted by 5 mm sections.
The 1 mm sections numbered consecutively were used for RNA
isolation, while the interrupted thin sections were prepared for
histopathological examination. In this way good tissue profiles
were obtained. The histopathological examinations made at the
Perinatal Pathology Section at the Karolinska Hospital gave
results as shown in Table 1.
Human fetal livers (7, 13 and 14 weeks old), were obtained
from therapeutic terminations, with the permission of the local
ethical committee. Due to the nature of such procedures limited
amounts of such tissues were obtained. For this reason, we were
unable to include any RNA from these samples in the analysis of
M6P/IGF2R and IGFBP-1.
Nucleic acid isolation
Total RNA was prepared as described previously (Chomczynski
and Sacchi, 1987).
Preparation of probe and RNase protection analysis
(RPA)
RNA probes were prepared from the above templates using T3 and
T7 RNA polymerases (Life Technologies) according to the
protocol provided in the RPA II Kit (Ambion). When incorpo-
rating radioactivity into the probe, radioactive 32P-UTP with a
specific activity of 800 Ci mmol–1 was used. Cold UTP was added
such that final probe activity was 400 Ci mmol–1 for all probes
except 80 Ci mmol–1 for the GAPDH probe.
The probes used in this study are as follows:
• Probes used to examine H19, total IGF2, IGF2 promoter P1,
IGF2 promoter P4 and IGF1 were generated as described
previously (Ohlsson et al, 1994; Ekström et al, 1995; Li et al,
1995, 1998a, 1998b; Olivecrona et al, 1999).
• To examine IGF2 promoter P2-specific transcripts, a Pst
I–SmaI fragment covering the 5¢-end of IGF2 exon 4 was
cloned into pBluescript SK II– vector (Stratagene, La Jolla,
CA, USA). When this plasmid was linearized with EcoRI, T3
RNA polymerase was used to transcribe a probe of 311 bases.
When used in RNAase protection analysis, 220 bp hybridized
to IGF2 P2-specific mRNA transcripts and was protected from
digestion.
• For IGF2 promoter P3-specific mRNA transcripts a blunted
SmaI–BglI specific to the 3¢-end of IGF2 exon 5 was cloned
into the EcoR V site of pBluescript SK II– vector (Stratagene).
After linearization of the resulting plasmid with EcoRI, T7
RNA polymerase could be used to transcribe a 298 bp RNA
probe. When used in a hybridization reaction, 111 bp of this
probe hybridizes specifically to IGF2 P3 mRNA transcripts.
• The M6P/IGF2R probe used in this series of experiments was
generated from plasmid p146 as previously described, which
allows the detection of the ACAA+/– polymorphism (Smrzka
et al, 1995). When linearized with HindIII an RNA probe of
269 bp could be generated with T3 RNA polymerase of which
either 147 bases (ACAA+) or 125 bases (ACAA–) will
hybridize to M6P/IGF2R-specific transcripts.
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Table 1 Samples used in this study
Case Age Pre-operative Histology Other features 1p LOH 11p LOH Outcome
(month)/ chemotherapy
sex
Matched pairs
HB 1 6  No Epithelial No Yes NED
HB 2 19  Yes Epithelial Liver tissue with bile stasis and multi-focal No Yes DOD
regions of hepatoblastoma
HB 3 19  Yes Epithelial Connective tissue present. Proliferating bile ducts No No NED
HB 4 22  Yes Mixed Liver tissue with fibrosis present No No NED
Epithelial/mesenchymal
HB 5 54  Yes Epithelial Connective tissue present Yes No NED
HB 6 2  No Fetal Vacuolized cytoplasm. Extra-medullary ? ? NED
haematopoesis. Metaplastic osteoids
HB 7 12  Yes Fetal Hepatocytes show trabecular and acinary cell ? ? NED
arrangment. Apoptotic cells with lymphocyte
infiltration, macrophages, proliferating capillaries
and foci of haematopoesis
HB 8 36  Yes Hepatoblastoma. No further information ? ? NED
Unmatched tumours
HB 9 11  No Fetal Some connective tissue septa No No NED
HB 10 13  No Epithelial Well differentiated hepatoblastoma No No NED
HB 11 8  No Mixed Some streaks of bone tissue No No NED
Epithelial/mesenchymal
Fetal Liver
7 week N/A N/A Normal N/A N/A N/A
13 week N/A N/A Normal N/A N/A N/A
14 week N/A N/A Normal N/A N/A N/A
Symbols used:  – male;  – female; LOH – loss of heterozygosity; NED – no evidence of disease; DOD – dead of disease; ? – Unknown; N/A – not
applicable.
o
o
o
o
o
o
o
o
o
+ o
+ o
+ o
+ o• The IGF1R probe used in this series of experiments was a gift
from Dr Gunnar Norstedt. After digestion of the plasmid with
PvuII, T3 RNA polymerase was used to generate a probe with
a size of 411 bases. When used in the protection assay 184
bases of these probe transcripts could hybridize specifically to
IGF1R mRNA.
• The GAPDH clone (pTRI-GAPDH-Human) used in these
experiments was purchased from Ambion. When hybridized to
mRNA this probe protects 315 bases from digestion. RNAase
protection was carried out according to the protocol given with
the RPA II Kit (Ambion).
Analysis of expression
Quantification of the results was obtained using phosphor imager
analysis (BAS-1000, Fuji Photo Film Co., Ltd) with GAPDH
mRNA levels utilized as the internal control in each case. In each
case the values for the gene under scrutiny were normalized to the
internal control. The average value for all the normal samples was
obtained and set as the arbitrary value for normal liver. The value
obtained for the tumours was therefore adjusted by multiplying the
obtained value by the ratio of the arbitrary normal value to the
matched normal liver.
Adjusted tumour value = Tumour value 3 (average value for
all the normals 4 matched normal value)
Example
Sample Original Average N Factor Adjusted sample
values value (Navg) values
T1 26 4
N1 32 6
(eg: average normal (Navg) = 6. A tumour (T1) has a value of 2 and
its matched normal (N1) has a value of 3. The factor (Navg4N1)
required to bring N1 up to Navg is 2. Both N1 and T1 are therefore
multiplied by two to give the final values as indicated N1 = 6 and
T1 = 4.
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Figure 1 RNase protection analysis of IGF2 and H19 expression. (A) Analysis of total IGF2 transcripts in hepatoblastomas. A single representative RNase
protection analysis for one of the matched tumours is shown. GAPDH expression is used as the internal control for quantification purposes. In all of the following
figures the Y-axis units represent the values for each gene divided by the value obtained for the housekeeping gene GAPDH (in this case: IGF2/GAPDH) as
determined by phosphorimager analysis and following the adjustments as described in Materials and Methods. The mean ± standard error of the mean was also
calculated for the tumours (T), normals (N) and fetal tissues (F), and graphed along with the individual samples. Matched tumours are those samples for which
normal liver was taken from the same individual at time of surgery. Unmatched tumours are those samples for which normal liver tissue was unavailable. Fetal
livers were included to compare against normal liver and tumour expression. (B) Analysis of H19 expression in hepatoblastomas. A representative RNase
protection analysis showing total H19 transcripts in one of the matched tumours is shown. Following quantification with the internal control (GAPDH), H19
expression for the matched samples was calculated and graphed as described above
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Figure 2 RNase protection analysis of M6P/IGF2R expression. Using
RNase protection analysis M6P/IGF2R transcripts were quantified and
graphed as described in Figure 1. However, due to a lack of available RNA at
the time of analysis the samples HB7 and HB8 were included in the
unmatched tumours, and no fetal tissues were examined. A representative
RNase protection analysis for one of the matched tumours is shownThe mean ± standard error of the mean was also calculated for
the tumours, normals and fetal tissues and graphed along with the
individual samples.
RESULTS
Expression of IGF2 and H19
We examined the total transcriptional activity, as well as the
relative activity from the different IGF2 promoters, and the
expression levels of H19 in a series of matched hepatoblastomas
and the corresponding normal liver tissue from patients between
the ages of 2 and 54 months (Table 1). Included in the analysis
were a series of hepatoblastomas with no counterpart normal
tissues and several fetal liver samples. In accordance with previ-
ously published results expression of IGF2 was increased in most
of the tumour samples when compared against corresponding
normal tissue, with two exceptions, HB1 and HB6 (Figure 1A) (Li
et al, 1995). The human IGF2 gene is transcribed from four
promoters (P1–P4). When IGF2 promoter usage was examined the
pattern of expression which emerged was as follows. The major
transcript produced by the hepatoblastomas was from promoter
P3, with increased expression from promoter P2, decreased
expression from promoter P4, and no expression from promoter P1
(data not shown). These results are in concordance with our previ-
ously publsihed results (Li et al, 1995, 1998B).
When H19 expression was examined, similar results to those
previously presented were observed (Li et al, 1995). In general, for
the hepatoblastomas, H19 expression was decreased (Figure 1B).
The one exception showing increased H19 expression in this series
of experiments is the sample HB3.
Expression of the M6P/IGF2R in normal versus tumour
tissue
As  IGF2 was increased in hepatoblastomas, we set out to
examine the expression of the mannose-6-phosphate/insulin-like
growth factor II receptor (M6P/IGF2R) in these tissues. One of the
roles of this receptor is to bind IGF-II. whereupon it is internalized
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Figure 3 RNase protection analysis of IGF1 and IGF1R expression. (A) Quantification of IGF1 transcripts in hepatoblastomas. A representative RNase
protection analysis is shown showing IGF1 and GAPDH protected fragments for two of the matched tumours. Following quantification, the results were graphed
as described in Figure 1. (B) Quantitative analysis of IGFIR expression. Representative results of the RNase protection analysis for two of the matched tumours
are shown. Following quantification with the internal control (GAPDH), IGFIR expression for the matched samples was calculated and graphed as described in
Figure 1
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Figure 4 RNase protection analysis of IGFBP-1 and IGFBP-2 expression. (A) Quantification of IGFBP-1 expression. A representative RNase protection
analysis showing IGFBP-1 and GAPDH transcripts in one of the matched hepatoblastoma samples is shown. The results were analysed and graphed as
detailed in Figure 1. Due to a lack of available RNA no fetal liver was examined for IGFBP-1 expression. (B) Quantitative analysis of IGFBP-2 expression.
A representative result of the RNase protection analysis is shown for one of the hepatoblastoma samples. Following quantification with the internal control
(GAPDH) by phosphorimager analysis, IGFBP-2 expression for the matched samples was calculated and graphed as described in Figure 1and subsequently degraded by lysosomes (De Souza et al, 1997).
The results of this analysis show that for some cases (notably HBs 1,
2, 8 and 11) expression of the receptor is decreased (Figure 2). The
degree of expression, however, varies between samples. Several of
the tumours show levels of expression which are close to the arbi-
trary normal value. Also, one sample HB10, shows an increased
expression of this gene. Due to a lack of available RNA at the time
of analysis the samples HB7 and HB8 were included in the
unmatched tumours (Figure 2).
IGF1 and IGF1R expression in hepatoblastomas
The expression profiles of the genes for IGF1 and the IGF1R were
then examined in our samples to see if there were any differences
between tumour versus normal tissues. The results are shown in
Figure 3. IGF1 expression showed a varied expression profile.
When the matched tumours are compared against the arbitrary
normal, two groups emerge, those that show increased IGF1
expression (samples HB3, HB5, HB7 and HB8), and those that
show decreased IGF1 expression (HB1, HB2 and HB6) (Figure
3A). The same result was observable if the individual RPA values
for each matched tissue set was compared without adjustment
(data not shown).
When  IGF1R expression was examined a similar expression
profile emerged (Figure 3B). Those samples which showed
increased  IGF1 expression also showed increased IGF1R expres-
sion and those showing decreased IGF1 expression correlated with
decreased IGF1R expression (Figure 3 A, B).
Expression of IGFBP-1 and IGFBP-2
Previously it was shown that the degree of tumour cell differentia-
tion correlated with over-expression of IGFBP-2 in hepato-
blastoma (Akmal et al, 1995). In their study, expression of
IGFBP-2 was high in poorly differentiated hepatoblastoma and
low in well differentiated hepatoblastoma. We examined the levels
of expression for both IGFBP-1 and IGFBP-2. The results of this
analysis are shown in Figure 4.
Expression of IGFBP-1 was shown to be decreased in most
tumours with the exceptions being samples HB3 and HB6. The
overall trend, however, appears to show greatly decreased expres-
sion of IGFBP-1 in hepatoblastomas (Figure 4A). Owing to the
limited amounts of tissue available we were unable to include fetal
liver in this analysis. IGFBP-2 expression was also decreased in
hepatoblastomas although the degree of the decrease varied. Some
samples (HB1, HBs 5–8, HB10 and HB11) showed large decreases
in  IGFBP-2 expression, whereas others (HBs 2–4, and HB9)
showed moderate or almost normal expression of IGFBP-2
(Figure 4B). The samples with low expression of IGFBP-2 have
similar expression levels as fetal liver (Figure 4B), whereas those
with moderate expression are clearly reduced from that of matched
normal liver (Figure 4B).
DISCUSSION
The IGF-axis plays an important role in many diverse cellular
functions including promotion of cell growth and cell survival.
Two genes encoding for insulin-like growth factors have been
identified,  IGF1 and IGF2. The main producer of circulating IGF-
I and IGF-II is the liver, and the ability of these peptides to mediate
mitogenic, anti-apoptotic and differentiation signals is likely to be
primarily via the IGF-IR (Rosen and Pollak, 1999). Regulation of
IGF-action is controlled in part by a family of proteins called the
insulin-like growth factor binding proteins. This family consists of
six high affinity IGFBPs and nine low affinity IGFBP-rPs
(Wetterau et al, 1999), each of which shows different tissue
specific production and regulatory functions (Rechler and
Clemmons, 1998). One of the major functions of IGFBPs is to
bind IGFs. By doing so, they form biologically inactive complexes
which modulate IGFs from binding to their receptors. The expres-
sion of two members of the IGF-axis have previously been shown
to be altered in hepatoblastomas (Akmal et al, 1995; Li et al,
1995). If such changes are important in the tumorigenesis or patho-
genesis of this disease, a more detailed examination of the IGF-
axis in hepatoblastoma may provide greater insights into this
disease. In this study we have examined a number of genes from
the IGF-axis, including the IGF1 and  IGF2, their receptors
(IGF1R and  M6P/IGF2R), and two members of the IGFBPs
(IGFBP-1 and  IGFBP-2) in a series of hepatoblastomas. The
results were compared to the expression levels for fetal liver and if
The IGF-axis and hepatoblastoma 1565
British Journal of Cancer (2000) 82(9), 1561–1567 © 2000 Cancer Research Campaign
Table 2 Results of gene expression analysis in the hepatoblastomas with respect to clinical outcome and histology
Case Outcome Histology IGF2 H19 M6P/IGF2R IGF1 IGF1R IGFBP-1 IGFBP-2
HB1 NED Epithelial N ¯¯ ¯ ¯ ¯ ¯
HB2 DOD Epithelial ­¯ ¯ ¯ ¯ ¯ ¯
HB3 NED Epithelial ­­ ¯ ­ ­ N ¯
HB4 NED Mixed Epithelial/Mesenchymal ­¯ ¯ ¯ ¯ ¯ ¯
HB5 NED Epithelial ­¯ N ­­¯ ¯
HB6 NED Fetal ¯¯ ¯ ¯ ¯ N ¯
HB7 NED Fetal N ¯ N ­­¯ ¯
HB8 NED N/A N ¯¯ ­ ­ ¯ ¯
HB9 NED Fetal N ¯¯ ­ N/D ¯ N
HB10 NED Epithelial ­¯ ­ ¯ N ¯¯
HB11 NED Mixed Epithelial/Mesenchymal N ¯¯ ­ ­ ¯ ¯
Symbols used: NED – no evidence of disease; DOD – dead of disease; N/D – not determined; N – normal expression; ­ – increased expression; ¯ – decreased
expression.available to matched normal liver obtained from the affected indi-
viduals at surgery. In this way we could see if expression differ-
ences at the individual level were related to the malignancy, and as
hepatoblastomas often share similarities to fetal hepatocytes the
results could also be compared to fetal liver. Our results demon-
strate that in the hepatoblastomas, the expression of many of the
IGF-axis genes are altered. An overview of these results is given in
Table 2.
Six of the hepatoblastoma samples had increased expression of
IGF1. Of these six samples, five also had increased IGF1R mRNA
levels. Thus the increased levels in these samples may be func-
tioning to promote tumour growth and suppress apoptosis. Of the
samples showing increased IGF1 and  IGF1R mRNA, three of
these (HBs 3, 5 and 7) have also been shown to have specifically
increased mRNA levels of important cell cycle regulators, growth
factors and cyclin-dependent kinase inhibitors (Gray et al, manu-
script submitted). In addition, two of these samples have an up-
regulation of three genes whose products have been shown to be
involved in apoptosis (Gray et al, manuscript submitted). Thus,
there may be a competition between apoptotic signals (increased
p21, TGF-b and IGFBP-3) and anti-apoptotic signals (increased
IGF-I) in these tumours.
The expression of IGF2 was also observed to be altered in the
hepatoblastomas. Of the 11 tumours available nine of these
showed an increased expression of IGF2. Only one sample (HB6)
showed a decrease in the levels of mRNA for this gene. This case
is unusual as it shows reduced expression of all genes except one
IGFBP-1 (Table 2).
When the levels of expression of the M6P/IGF2R receptor were
examined, most of the tumours showed decreased or normal levels
of mRNA for this gene. As one of the functions of the product of
this gene is to bind IGF-II for subsequent internalization and
degradation by lysosomes (De Souza et al, 1997), an increase in
expression of IGF2 without a concommitant increase in the
expression of M6P/IGF2R may indicate that the cells in these
tumours have an increased mitogenic potential due to the increase
in IGF2 and IGF1. In some situations this mitogenic potential is
further increased by having increased levels of IGF1R (increased
signalling potential) most notably HB3 and HB5. When levels of
IGFBP-1 and IGFBP-2 mRNA were examined, the results show
that for nearly all samples, expression of these genes are reduced
in the tumours. IGFBP-1 has been shown to be the predominant
IGFBP in amniotic fluid and fetal plasma. In the liver, expression
of this gene in parenchymal cells has been demonstrated. Low
levels of IGFBP-1 protein have been correlated with fetal over-
growth (Spagnoli and Rosenfeld, 1997). Nine of 11 tumour
samples show decreased expression of IGFBP-1 mRNA.
Therefore the reduction in the mRNA may be reflected in the
protein levels, leading to increased tumour growth potential, in a
manner similar to that observed for fetal overgrowth. However,
one of the hepatoblastomas classified as a fetal type, shows normal
IGFBP-1 mRNA levels when compared to its matched normal
liver. As no examination of IGFBP-1 mRNA in fetal tissue was
carried out in this study, a distinct correlation between the levels of
this genes mRNA to overgrowth cannot be assumed. Further
experiments should be carried out including immunohistochem-
istry for this protein to see if such a correlation exists. IGFBP-2
has been shown to be produced in the liver by Kupffer and
parenchymal cells. An early report by Ikeda and collegues showed
that  IGFBP-2 expression was altered in hepatoblastomas. This
study showed that well differentiated tumours and normal liver
had no detectable IGFBP-2 or IGF2 expression, whereas poorly
differentiated tumours had high expression of IGFBP-2 (Akmal et
al, 1995). In contrast to this report we have shown that normal
liver produces comparably large quantities of detectable IGFBP-2
mRNA (Figure 4B). One of the functions of the IGFBPs is to bind
IGFs, and by doing so they form biologically inactive complexes
which affect the the ability of the IGFs to bind to its receptors. As
IGFBP-1 and IGFBP-2 mRNA is reduced in most tumours, excess
biologically active IGFs may therefore be available in these
tumours to potentiate proliferative effects. In addition to these
IGFBPs, we have also examined the expression of ALS, two other
IGFBPs (IGFBP-3 and  IGFBP-5) and IGFBP-rP1 in these
tumours (Gray et al, manuscript submitted, data not shown). The
results show that the levels of all of these genes are affected in
these tumours.
In addition to examining the IGF-axis we also examined the
expression of the potential tumour suppressor H19, in these
samples. In ten of the 11 samples, expression of this gene was
reduced. As one of the proposed functions of this gene is to
suppress growth, down-regulation of the gene may therefore
predispose the hepatoblastomas to overgrowth. This may be
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Table 3 Results of the gene expression analysis in the hepatoblastomas with respect to the average fetal liver expression
Case Histology IGF2 H19 IGF1 IGF1R IGFBP-2
HB1 Epithelial ¯ ¯¯¯N
HB2 Epithelial ¯ ¯¯¯­
HB3 Epithelial N ­­­­
HB4 Mixed epithelial/mesenchymal ­ ¯¯¯­
HB5 Epithelial ¯ ¯­­¯
HB6 Fetal ¯ N ¯¯­
HB7 Fetal ¯ ¯­­N
HB8 N/A ¯¯ NN­
HB9 Fetal ¯¯ N N/D ­
HB10 Epithelial ¯ N ¯ N ­
HB11 Mixed epithelial/mesenchymal ¯¯ ­ NN
Symbols used: N/D – not determined; N – normal; ­ – increased expression; ¯ – decreased expression.particularly important for the tumour HB1. In this tumour expres-
sion of every gene except IGF2 is decreased (Table 2). In this
sample expression of IGF2 is normal, but levels of M6P/IGF2R,
IGFBP-1 and IGFBP-2 are decreased, and H19 is also greatly
decreased. Thus, there may be increased levels of active IGF-II to
potentiate growth signals, and the lack of H19 expression may
amplify this response.
The alterations in expression of members of the IGF-axis do not
appear to correlate with the clinical outcome of this disease. Only
one patient failed to achieve clinical remission, and the expression
profile for this individual (HB2), is similar to that for another indi-
vidual (HB4), who shows no evidence of the disease following
surgical intervention (Table 2). There also appears to be no corre-
lation between gene expression differences and tumour type as no
tumour type can be separated from the others on the basis of gene
expression differences examined here (Table 2). It may be argued
that the expression patterns observed indicate a tendency towards a
fetal liver phenotype.
When the expression profiles against the average fetal liver
expression were compared, we were unable to discover any such
correlations (Table 3). One might also argue that there may be
normal cells present within some of the tumour samples which
may affect the analysis by masking any alterations in expression.
This may be especially true for those samples in which gene
expression from the tumour is similar to that observed for normal
liver (Table 2). In such cases, a more comprehensive analysis
could be determined using techniques such as in situ hybridization.
Alternatively micro-dissection of the tumours may provide tumour
rich mRNA for analysis. Such studies are in the process of being
initiated.
In conclusion, the IGF-axis is affected in hepatoblastomas.
While there are no definitive explanations on the role these alter-
ations may play in the tumorigenesis process, one potential result
of these alterations may be that local concentrations of IGFs in
combination with reduced levels of IGFBPs promote clonal expan-
sion of the tumour cells. Further studies are indicated for in order
to determine the exact importance of the IGF-axis in hepato-
blastomas.
REFERENCES
Akmal SN, Yun K, MacLay J, Higami Y and Ikeda T (1995) Insulin-like growth
factor 2 and insulin-like growth factor binding protein 2 expression in
hepatoblastoma. Hum Pathol 26: 846–851
Albrecht S, von Schweinitz D, Waha A, Kraus JA, von Deimling A and Pietsch T
(1994) Loss of maternal alleles on chromosome arm 11p in hepatoblastoma.
Cancer Res 54: 5041–5044
Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:
156–159
Constancia M, Pickard B, Kelsey G and Reik W (1998) Imprinting mechanisms.
Genome Res 8: 881–900
De Souza AT, Yamada T, Mills JJ and Jirtle RL (1997) Imprinted genes in liver
carcinogenesis. FASEB 11: 60–67
Ekström TJ, Cui H, Li X and Ohlsson R (1995) Promoter-specific IGF2 imprinting
status and its plasticity during human liver development. Development 121:
309–316
Franklin GC, Adam GI and Ohlsson R (1996) Genomic imprinting and mammalian
development. Placenta 17: 3–14
Li X, Adam G, Cui H, Sandstedt B, Ohlsson R and Ekström TJ (1995) Expression,
promoter usage and parental imprinting status of insulin-like growth factor II
(IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting.
Oncogene 11: 221–229
Li X, Gray SG, Flam F, Pietsch T and Ekström TJ (1998a) Developmental-
dependent DNA methylation of the IGF2 and H19 promoters is correlated to
the promoter activities in human liver development. Int J Dev Biol 42:
687–693
Li X, Kogner P, Sandstedt B, Haas OA and Ekström TJ (1998b) Promoter-specific
methylation and expression alterations of igf2 and h19 are involved in human
hepatoblastoma. Int J Cancer 75: 176–180
Looijenga LH, Verkerk AJ, De Groot N, Hochberg AA and Oosterhuis JW (1997)
H19 in normal development and neoplasia. Mol Reprod Dev 46: 419–439
Montagna M, Menin C, Chieco-Bianchi L and E D’Andrea (1994) Occasional loss
of constitutive heterozygosity at 11p15.5 and imprinting relaxation of the IGFII
maternal allele in hepatoblastoma. J Cancer Res Clin Oncol 120: 732–736
Morison IM and Reeve AE (1998) Insulin-like growth factor 2 and overgrowth:
molecular biology and clinical implications. [Review]. Mol Med Today 4:
110–115
Odell SD and Day IN (1998) Insulin-like growth factor II (IGF-II). Int J Biochem
Cell Biol 30: 767–771
Ohlsson R, Hedborg F, Holmgren L, Walsh C and Ekström TJ (1994) Overlapping
patterns of IGF2 and H19 expression during human development: biallelic
IGF2 expression correlates with a lack of H19 expression. Development 120:
361–368
Olivecrona H, Hilding A, Ekström C, Barle H, Nyberg B, Moller C, Delhanty PJ,
Baxter RC, Angelin B, Ekström TJ and Tally M (1999) Acute and short-term
effects of growth hormone on insulin-like growth factors and their binding
proteins: serum levels and hepatic messenger ribonucleic acid responses in
humans. J Clin Endocrinol Metab 84: 553–560
Rainier S, Dobry CJ and Feinberg AP (1995) Loss of imprinting in hepatoblastoma.
Cancer Res 55: 1836–1838
Rechler MM and Clemmons DR (1998) Regulatory actions of insulin-like growth
factor binding proteins. Trends Endocrinol Metab 9: 176–183
Rosen CJ and Pollak M (1999) Circulating IGF-I: new perspectives for a new
century. Trends Endocrinol Metab 10: 136–141
Sainati L, Leszl A, Stella M, Montaldi A, Perilongo G, Rugge M, Bolcato S,
Iolascon A and Basso G (1998) Cytogenetic analysis of hepatoblastoma:
hypothesis of cytogenetic evolution in such tumors and results of a multicentric
study. Cancer Genet Cytogenet 104: 39–44
Smrzka OW, Fae I, Stoger R, Kurzbauer R, Fischer GF, Henn T, Weith A and
Barlow DP (1995) Conservation of a maternal-specific methylation signal at
the human IGF2R locus. Hum Mol Genet 4: 1945–1952
Spagnoli A and Rosenfeld RG (1997) Insulin-like growth factor binding proteins.
Curr Opin Endocrinol Diabetes 4: 1–9
Wetterau LA, Moore MG, Kuk-Wah L, Shim ML and Cohen P (1999) Novel aspects
of the insulin-like growth factor binding proteins. Mol Genet Metab 68:
161–181
von Schweinitz D, Wischmeyer P, Leuschner I, Schmidt D, Wittekind C, Harms D
and Mildenberger H (1994) Clinico-pathological criteria with prognostic
relevance in hepatoblastoma. Eur J Cancer 30A: 1052–1058
Yun K, Jinno Y, Sohda T, Niikawa N and Ikeda T (1998) Promoter-specific insulin-
like growth factor 2 gene imprinting in human foetal liver and hepatoblastoma.
J Pathol 185: 91–98
The IGF-axis and hepatoblastoma 1567
British Journal of Cancer (2000) 82(9), 1561–1567 © 2000 Cancer Research Campaign